stoxline Quote Chart Rank Option Currency Glossary
Cyclerion Therapeutics, Inc. (CYCN)
2.3673  0.067 (2.93%)    12-06 14:53
Open: 2.46
High: 2.46
Volume: 921
Pre. Close: 2.3
Low: 2.355
Market Cap: 6(M)
Technical analysis
2023-12-06 4:20:44 PM
Short term     
Mid term     
Targets 6-month :  3.14 1-year :  3.83
Resists First :  2.69 Second :  3.27
Pivot price 2.16
Supports First :  1.75 Second :  1.45
MAs MA(5) :  2.34 MA(20) :  2.19
MA(100) :  3.14 MA(250) :  6.62
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  39.4 D(3) :  41.9
RSI RSI(14): 49.4
52-week High :  19.13 Low :  1.75
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CYCN ] has closed below upper band by 20.7%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.46 - 2.48 2.48 - 2.49
Low: 2.34 - 2.35 2.35 - 2.36
Close: 2.35 - 2.37 2.37 - 2.39
Company Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 04 Dec 2023
Dr Regina Graul Appointed as President of Cyclerion Therapeutics A New Era of Innovation and Success - Best Stocks

Mon, 04 Dec 2023
Cyclerion Therapeutics appoints Graul as President - Seeking Alpha

Thu, 30 Nov 2023
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - Yahoo Finance

Tue, 28 Nov 2023
Insider Buyers At Cyclerion Therapeutics Likely Disappointed With 16% Slide - Simply Wall St

Wed, 02 Aug 2023
The Petri Dish: Alexion buys Pfizer gene therapies; Peter Hecht's plan to save Cyclerion assets - Boston Business Journal - The Business Journals

Tue, 01 Aug 2023
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 1.3e+006 (%)
Held by Institutions 13.8 (%)
Shares Short 18 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.809e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 871.9 %
Return on Equity (ttm) -118.4 %
Qtrly Rev. Growth 1.33e+006 %
Gross Profit (p.s.) 0
Sales Per Share -153.47
EBITDA (p.s.) 0
Qtrly Earnings Growth -18.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -27 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.81
Stock Dividends
Dividend 0
Forward Dividend 13310
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android